Relief Therapeutics

211 articles with Relief Therapeutics

• Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023

  3/22/2023

  RELIEF THERAPEUTICS Holding SA announces survey results identifying preferred urea cycle disorder treatment attributes from its collaboration partner ACER Therapeutics, Inc.

• Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

  3/17/2023

  RELIEF THERAPEUTICS Holding SA announced the Company will present the results of pre-clinical research evaluating the metabolic impact of PKU GOLIKE® on nitrogen balance, muscle strength and glucose.

• Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe

  3/16/2023

  RELIEF THERAPEUTICS Holding SA is pleased to announce the availability of the newest PKU GOLIKE BARs ® in Europe.

• Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA

  3/15/2023

  RELIEF THERAPEUTICS Holding SA announces that its collaboration partner, ACER Therapeutics, Inc., has provided an update on commercial launch activities for OLPRUVA™.

• Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars

  2/28/2023

  RELIEF THERAPEUTICS Holding SA is pleased to recognize Rare Disease Day 2023 and announce the U.S. availability of the new PKU GOLIKE™ bars, a medical food for the dietary management of phenylketonuria.

• Relief Therapeutics Provides an Update on its Financing Strategy

  2/8/2023

  RELIEF THERAPEUTICS Holding SA, provided an update on its financing strategy and the decision to voluntarily withdraw its Registration Statement on Form F-1 initially filed with the United States Securities and Exchange Commission on Aug. 23, 2022 in order to explore alternative options for financing, including non-dilutive sources of capital, with the goal of listing its ordinary shares on the Nasdaq Stock Market.

• Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

  1/17/2023

  RELIEF THERAPEUTICS Holding SA announced independent institutional review board approval for the protocol of an investigator-initiated trial to evaluate RLF-TD011 as an adjunctive treatment for patients diagnosed with cutaneous t-cell lymphoma.

• Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

  12/27/2022

  RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 2 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission relating to a proposed offering of its ordinary shares in the form of American Depositary Shares.

• Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements-December 20, 2022

  12/20/2022

  RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. a clinical-stage central nervous system biopharmaceutical company, today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals' wholly owned subsidiary, NeuroRx, Inc.

• Relief Therapeutics to Participate in January 2023 Investor Meetings

  12/14/2022

  RELIEF THERAPEUTICS Holding SA announced the Company will present at the 15 th Annual Biotech Showcase TM and host institutional investor meetings at the event, as well as at the 12 th Annual LifeSci Partners Corporate Access Event.

• Relief Therapeutics Announces Issuance of Shares from Authorized Capital

  12/13/2022

  RELIEF THERAPEUTICS Holding SA reported that its board of directors approved an increase of the Company's share capital from 4,616,334,617 to 5,616,334,617 shares through the issuance of 1,000,000,000 shares from its authorized capital.

• RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement

  10/26/2022

  RELIEF THERAPEUTICS Holding SA today announced that they and NRx Pharmaceuticals, Inc. have agreed to extend the stay of their pending litigation until November 7, 2022 to allow time for the parties to finalize their tentative litigation settlement.

• Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

  10/25/2022

  RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 2 to its Form F-6 registration statement for depositary shares evidenced by American Depositary Receipt with the U.S. Securities and Exchange Commission.

• Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer

  10/14/2022

  RELIEF THERAPEUTICS Holding SA, a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, announced that Paolo Galfetti has been promoted to Chief Operating Officer, effective October 14, 2022.

• Relief Announces U.S. Launch of PKU GOLIKE

  10/10/2022

  RELIEF THERAPEUTICS Holding SA today announced the U.S. launch of PKU GOLIKE® - a next generation medical food product engineered with the patent protected, pharmaceutical grade Physiomimic™ technology for the dietary management of phenylketonuria (PKU).

• Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.

  10/6/2022

  RELIEF THERAPEUTICS Holding SA announced that it has hired a leading national health services company to serve as exclusive distributor of PKU GOLIKE ® in the U.S. PKU GOLIKE ® is a next generation medical food product engineered with the patent protected, pharmaceutical grade Physiomimic™ technology for the dietary management of phenylketonuria, and has been commercialized in the EU since 2019.

• Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate

  10/3/2022

  Acer Therapeutics Inc. and RELIEF THERAPEUTICS Holding SA today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Acer for US patent application No. 16/624,834 for claims related to a kit comprising a combination therapeutic product composed of sodium phenylbutyrate or glycerol phenylbutyrate and sodium benzoate.

• Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago

  9/22/2022

  RELIEF THERAPEUTICS Holding SA announced that an Investigator Initiated Trial with Nexodyn for Epidermolysis Bullosa has received IRB approval and will shortly enroll participants at Ann & Robert H. Lurie Children's Hospital of Chicago with Professor Amy Paller, M.D., Chair, Department of Dermatology, Feinberg School of Medicine, Northwestern University, serving as Principal Investigator.

• Relief Reports Half-Year 2022 Results and Provides Corporate Update

  9/15/2022

  RELIEF THERAPEUTICS Holding SA reported its results for the half-year ended June 30, 2022 and provided a corporate update.

• Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

  9/12/2022

  RELIEF THERAPEUTICS Holding SA announced that Jack Weinstein, Chief Financial Officer and Treasurer, will participate in a panel discussion and present a company overview during the 22 nd Annual Biotech in Europe Forum, being held September 21-22, 2022, in Basel, Switzerland.